Coloplast (COLOb.CO) has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up to $1.3 billion, the Danish medical equipment maker said. Coloplast said it would finance the deal by raising equity. “Kerecis represents an attractive opportunity to strategically strengthen Coloplast’s presence in the advanced wound care market by entering the high-growth, U.S.-centric biologics segment,” the Danish firm said in a statement.
Read the full article: Coloplast Buys Fish Skin Woundcare Firm for up to $1.3B //
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/denmarks-coloplast-buys-kerecis-up-13-bln-2023-07-07